Single Cell Spatial Transcriptomics Shared Instrument at the BCM Core Facility

摘要 单细胞组学是一个快速发展的新领域，它比传统的“大块”组织具有许多优势 分析方法，如解决细胞类型中组织内异质性的能力， 微环境，并研究罕见的亚群。然而，当前单电池的主要缺点之一是， 转录组技术的缺点是，它们需要分离单细胞，导致空间信息的丢失。 信息.为了解决这一问题，空间单细胞转录组学技术最近已经被应用于 这将带来许多新的研究机会。所要求的仪器，MERSCOPE 是目前唯一的商业平台，用于最近开发的多路复用错误鲁棒性 荧光原位杂交（MERFISH）技术，允许在单细胞中进行原位转录组分析 分辨率通过利用错误鲁棒和纠错编码方案，MERFISH能够大规模地 多重单分子RNA成像具有高灵敏度和准确性。共享的MERSCOPE 仪器将被放置在已建立的单细胞基因组学核心（SCGC）并由其管理， 确保操作顺畅，方便取用。我们已经确定了16个研究小组，在tumas用户。 这些研究小组共有41个由NIH资助的活跃研究项目，将使用美国国家卫生研究院90%的能力。 工具。这些项目的研究重点是高度多样化的，他们是由十五个资助。 NIH的研究所，包括NICHD、NIAMS、NIDC、NCATS、NIDDK、NEI、NCI、NIA、NIGMS、NHLBI， NHGRI、NINDS、NIAID、NIEHS和NIMDH。由于参与计划的主要私家医生均从事基础及临床工作， 我们相信，这一新工具的引入将对以下方面产生直接、广泛和直接的影响： 许多医学相关领域。

Abstract Single-cell omics is a rapidly growing new field that provides many advantages over traditional ‘bulk’ tissue profiling methods, such as the ability to resolve intratissue heterogeneity in cell types, profile disease microenvironments, and study rare subpopulations. However, one of the major drawbacks of current single-cell transcriptome technologies is that they require the isolation of single cells, resulting in the loss of spatial information. To address this issue, spatial single-cell transcriptomics technologies have been recently developed, which will enable many new research opportunities. The requested instrument, the MERSCOPE from Vizgen, is currently the only commercial platform for the recently developed multiplexed error-robust fluorescence in situ hybridization (MERFISH) technology that allows in situ transcriptome profiling at single cell resolution. By utilizing error-robust and error-correcting encoding schemes, MERFISH enables massively multiplexed single-molecule RNA imaging with high sensitivity and accuracy. The shared MERSCOPE instrument will be placed at and administrated by the established BCM Single Cell Genomics Core (SCGC) to ensure smooth operation and easy access. We have identified 16 research groups at BCM as users. Together, these groups have 41 active research projects funded by the NIH and will use 90% of the capacity of the instrument. The research focuses of these projects are highly diverse, and they are funded by fifteen institutes at the NIH, including the NICHD, NIAMS, NIDC, NCATS, NIDDK, NEI, NCI, NIA, NIGMS, NHLBI, NHGRI, NINDS, NIAID, NIEHS, and NIMDH. As the participating PIs are all engaged in both basic and clinical research, we believe the introduction of this new instrument will have direct, broad, and immediate impact on many medically relevant fields.